



Antonio Cardarelli
AZIENDA OSPEDALIERA DI RILIEVO NAZIONALE

TMD URO – ONCOLOGICO

**I nuovi Farmaci nel carcinoma renale e
vescicale:
Potenzialità e Criticità**




III° INCONTRO REGIONALE



tmd
uro onco

team
multidisciplinare
uro oncologico





Level and grade of recommendation for first-line pazopanib and sunitinib are the same in 2016 RCC guidelines from AIOM, EAU, ESMO and NCCN



CARCINOMA RENALE

CARCINOMA RENALE METASTATICO

LA SCELTA DELLA PRIMA LINEA



Motzer et al., N Engl J Med. 2007 11;356(2):115

Comparz trial: Motzer et al. N Engl J Med. 2013;22;369(8):722-31.

Motzer et al N Engl J Med. 2007 Jan 28;356(2):115-24

Choueiri et al. / E. J. C. 94 (2018) 115-125

Motzer et al N Engl J Med. 2018 Mar 28

IMmotion151 J. Clin Oncol 2018

Motzer RJ, ESMO 2018


Motzer RJ, et al. J Clin Oncol 2013

G. Carteni 2019

° End point primario

CARCINOMA RENALE METASTATICO

Sequenze Terapeutiche OUTCOME e QoL



Rini et al., Lancet 2011. 2011;378;1931;
D. Cella et al., British Journal of Cancer (2013) 108, 15718


Choueiri et al., N Eng J Med 2015;373;1814;
D. Cella Annals of Oncology 27 (Supp. 6): vi266–vi295, 2016
D. Cella et al., N Engl J Med 2018 February 12, 201

Motzer et al., Lancet Oncol, 2015; 16;1473

Motzer et al., N. Engl J Med 2015;373;1803

Motzer et al., Cancer. 2010; 15;116(18):4256


Treatment Related Adverse Events in Front Line metastatic ccRCC



Javelin: Gr 3-5 51% and gr 1-2 44%


Systemic therapy for urothelial cancer

Approval of 5 new immunotherapeutic agents



CARCINOMA UROTELIALE METASTATICO

Sequenze Terapeutiche OUTCOME



Von der Maase h. J Clin Oncol. 2000 Sep;18(17):3068-77.

Sternberg CN. J Clin Oncol. 2001; 19:2638-2646.



De Santis M. J Clin Oncol 2012; 30:191-199

Balar AV. Lancet 2017; 389:67-76

Balar AV et al. Lancet Oncol 2017

→
Raccomandato per OS*

→
Raccomandato per PFS or ORR
PDL1 + > 10%

→

Raccomandato in mancanza di altre opzioni

G. Carteni 2018

1° linea


2° linea

3° linea

* End point primario

CARCINOMA UROTELIALE METASTATICO

Sequenze Terapeutiche OUTCOME



G. Carteni 2018

° End point primario

Bellmunt J *et al.* J Clin Oncol 2009;27:4454-4461

Stadler WM. *et al.* J Clin Oncol 1997;15:3394-3398

McCaffrey JA *et al.* J Clin Oncol 1997;15:1853-1857

Rosenberg JE *et al.* Lancet 2017;387:1909-1920

Bellmunt J *et al.* N Engl J Med. 2017;376:1015-1026
J Clin Oncol 36. © 2018


Sharma P [Lancet Oncol.](#) 2017 Mar;18(3):312-322.

Massard C. *et al.* J Clin Oncol 2016;34:31 19-3125

Apolo AB. *et al.* J Clin Oncol 2017;

CARCINOMA UROTELIALE METASTATICO


Sequenze Terapeutiche OUTCOME



G. Carteni 2018

* End point primario

Treatment-Related AEs Occurring in $\geq 10\%$ of Patients^a



^aOf patients in either treatment arm.
 7.5% febrile neutropenia in the chemotherapy arm.
 Data cutoff date: October 26, 2017.